http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 08:34:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MBX+Biosciences%2C+Inc.+++++For%3A+Aug+27/26985528.html si-local-file:///var/storage/secattach/20260827/26985528.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MBX+Biosciences%2C+Inc.+++++For%3A+Aug+27/26985528.html Thu, 27 Aug 2026 08:34:00 -0400 MBX O.67271574 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MBX+Biosciences%2C+Inc.+++++For%3A+Aug+27/26985528.html si-local-file:///var/storage/secattach/20260827/26985528.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MBX+Biosciences%2C+Inc.+++++For%3A+Aug+27/26985528.html Thu, 27 Aug 2026 08:34:00 -0400 MBX O.67271574 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html <p>MBX Biosciences, Inc. (Nasdaq: MBX) announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism, according to a company statement dated Aug. 27, 2026.</p> <p>The trial (NCT07699471) is a global, multicenter, randomized, double-blind, placebo-controlled study. Approximately 160 adults with chronic hypoparathyroidism will be enrolled and randomized 3:1 to receive canvuparatide or placebo during a 26-week double-blind treatment period, followed by a 78-week open-label extension.</p> <p>The 26-week treatment period includes a four-week fixed-dose period at 600 micrograms once weekly, an 18-week individualized dose-titration period of up to 1,600 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html Thu, 27 Aug 2026 08:01:41 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html <p>MBX Biosciences, Inc. (Nasdaq: MBX) announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism, according to a company statement dated Aug. 27, 2026.</p> <p>The trial (NCT07699471) is a global, multicenter, randomized, double-blind, placebo-controlled study. Approximately 160 adults with chronic hypoparathyroidism will be enrolled and randomized 3:1 to receive canvuparatide or placebo during a 26-week double-blind treatment period, followed by a 78-week open-label extension.</p> <p>The 26-week treatment period includes a four-week fixed-dose period at 600 micrograms once weekly, an 18-week individualized dose-titration period of up to 1,600 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html Thu, 27 Aug 2026 08:01:41 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html <p>MBX Biosciences, Inc. (Nasdaq: MBX) announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism, according to a company statement dated Aug. 27, 2026.</p> <p>The trial (NCT07699471) is a global, multicenter, randomized, double-blind, placebo-controlled study. Approximately 160 adults with chronic hypoparathyroidism will be enrolled and randomized 3:1 to receive canvuparatide or placebo during a 26-week double-blind treatment period, followed by a 78-week open-label extension.</p> <p>The 26-week treatment period includes a four-week fixed-dose period at 600 micrograms once weekly, an 18-week individualized dose-titration period of up to 1,600 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html Thu, 27 Aug 2026 08:01:41 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html <p>MBX Biosciences, Inc. (Nasdaq: MBX) announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism, according to a company statement dated Aug. 27, 2026.</p> <p>The trial (NCT07699471) is a global, multicenter, randomized, double-blind, placebo-controlled study. Approximately 160 adults with chronic hypoparathyroidism will be enrolled and randomized 3:1 to receive canvuparatide or placebo during a 26-week double-blind treatment period, followed by a 78-week open-label extension.</p> <p>The 26-week treatment period includes a four-week fixed-dose period at 600 micrograms once weekly, an 18-week individualized dose-titration period of up to 1,600 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html Thu, 27 Aug 2026 08:01:41 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html <p>MBX Biosciences, Inc. (Nasdaq: MBX) announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism, according to a company statement dated Aug. 27, 2026.</p> <p>The trial (NCT07699471) is a global, multicenter, randomized, double-blind, placebo-controlled study. Approximately 160 adults with chronic hypoparathyroidism will be enrolled and randomized 3:1 to receive canvuparatide or placebo during a 26-week double-blind treatment period, followed by a 78-week open-label extension.</p> <p>The 26-week treatment period includes a four-week fixed-dose period at 600 micrograms once weekly, an 18-week individualized dose-titration period of up to 1,600 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html Thu, 27 Aug 2026 08:01:41 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html <p>MBX Biosciences, Inc. (Nasdaq: MBX) announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism, according to a company statement dated Aug. 27, 2026.</p> <p>The trial (NCT07699471) is a global, multicenter, randomized, double-blind, placebo-controlled study. Approximately 160 adults with chronic hypoparathyroidism will be enrolled and randomized 3:1 to receive canvuparatide or placebo during a 26-week double-blind treatment period, followed by a 78-week open-label extension.</p> <p>The 26-week treatment period includes a four-week fixed-dose period at 600 micrograms once weekly, an 18-week individualized dose-titration period of up to 1,600 http://www.streetinsider.com/FDA/MBX+Biosciences+doses+first+patient+in+Phase+3+hypoparathyroidism+trial/26985091.html Thu, 27 Aug 2026 08:01:41 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Press+Releases/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html <p align="center"><em>Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable <br/>one-year clinical benefit</em></p> <p align="center"><em>Global registrational trial to enroll approximately 160 adults with HP to support once-weekly <br/>canvuparatide’s potential as a best-in-class PTH replacement therapy</em></p> <p>CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical http://www.streetinsider.com/Globe+Newswire/MBX+Biosciences+Announces+First+Patient+Dosed+in+Pivotal+Phase+3+oPTimize+Trial+of+Once-Weekly+Canvuparatide+in+Adults+with+Hypoparathyroidism/26984966.html Thu, 27 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 MBX O.20026344 O.22422661 O.67271574 http://www.streetinsider.com/New+Coverage/JPMorgan+Reinstates+MBX+Biosciences+Inc+%28MBX%29+at+Overweight/26957780.html <p>JPMorgan analyst Jessica Fye reinstates coverage on MBX Biosciences Inc (NASDAQ: MBX) with a Overweight rating and a price target of $88.00.</p> <p>For an analyst ratings summary and ratings history on MBX Biosciences Inc <a href="http://www.streetinsider.com/rating_history.php?q=MBX">click here</a>. For more ratings news on MBX Biosciences Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=MBX&amp;type=analyst">click here</a>.</p> <p>Shares of MBX Biosciences Inc closed at $66.35 yesterday.</p> http://www.streetinsider.com/New+Coverage/JPMorgan+Reinstates+MBX+Biosciences+Inc+%28MBX%29+at+Overweight/26957780.html Fri, 21 Aug 2026 03:27:57 -0400 MBX http://www.streetinsider.com/SEC+Filings/Form++144++++++++MBX+Biosciences%2C+Inc.++++++++++++++++++Filed+by%3A+Hawryluk+P.+Kent/26937750.html si-local-file:///var/storage/secattach/20260817/26937750.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++MBX+Biosciences%2C+Inc.++++++++++++++++++Filed+by%3A+Hawryluk+P.+Kent/26937750.html Mon, 17 Aug 2026 15:41:00 -0400 MBX O.67271574 http://www.streetinsider.com/SEC+Filings/Form++144++++++++MBX+Biosciences%2C+Inc.++++++++++++++++++Filed+by%3A+Hawryluk+P.+Kent/26937750.html si-local-file:///var/storage/secattach/20260817/26937750.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++MBX+Biosciences%2C+Inc.++++++++++++++++++Filed+by%3A+Hawryluk+P.+Kent/26937750.html Mon, 17 Aug 2026 15:41:00 -0400 MBX O.67271574 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MBX+Biosciences%2C+Inc.++++++++++++++++++Filed+by%3A+Deep+Track+Capital%2C+LP/26925072.html si-local-file:///var/storage/secattach/20260814/26925072.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MBX+Biosciences%2C+Inc.++++++++++++++++++Filed+by%3A+Deep+Track+Capital%2C+LP/26925072.html Fri, 14 Aug 2026 08:28:00 -0400 MBX O.67271574 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MBX+Biosciences%2C+Inc.++++++++++++++++++Filed+by%3A+Deep+Track+Capital%2C+LP/26925072.html si-local-file:///var/storage/secattach/20260814/26925072.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MBX+Biosciences%2C+Inc.++++++++++++++++++Filed+by%3A+Deep+Track+Capital%2C+LP/26925072.html Fri, 14 Aug 2026 08:28:00 -0400 MBX O.67271574